Indaptus Therapeutics Stock Performance
| INDP Stock | USD 0.70 0.02 2.82% |
The company retains a Market Volatility (i.e., Beta) of -0.0105, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Indaptus Therapeutics are expected to decrease at a much lower rate. During the bear market, Indaptus Therapeutics is likely to outperform the market. At this point, Indaptus Therapeutics has a negative expected return of -0.31%. Please make sure to check out Indaptus Therapeutics' treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Indaptus Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Indaptus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Last Split Factor 1:4 | Dividend Date 2020-10-30 | Last Split Date 2021-07-27 |
1 | Disposition of 250 shares by Hayes William B of Indaptus Therapeutics at 355.2 subject to Rule 16b-3 | 01/06/2025 |
2 | Indaptus Therapeutics, Inc. Announces 2. ... | 01/13/2025 |
3 | Indaptus Therapeutics looks to raise 2.25M in private placement - MSN | 01/15/2025 |
4 | Discretionary transaction by Michael Newman of tradable shares of Indaptus Therapeutics subject to Rule 16b-3 | 01/16/2025 |
5 | Indaptus Therapeutics expands cancer trial to Canada - Investing.com India | 02/06/2025 |
6 | Indaptus Therapeutics Trading Down 0.6 percent Should You Sell - Defense World | 02/24/2025 |
7 | Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit | 02/25/2025 |
8 | Symbol Lookup | 03/12/2025 |
9 | Indaptus Therapeutics Posts Earnings Results, Beats Expectations By 0.03 EPS | 03/13/2025 |
10 | Disposition of 625 shares by Nir Sassi of Indaptus Therapeutics at 436.8 subject to Rule 16b-3 | 03/14/2025 |
11 | Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint ... | 03/18/2025 |
12 | Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20 | 03/20/2025 |
| Begin Period Cash Flow | 13.4 M |
Indaptus |
Indaptus Therapeutics Relative Risk vs. Return Landscape
If you would invest 91.00 in Indaptus Therapeutics on December 24, 2024 and sell it today you would lose (19.00) from holding Indaptus Therapeutics or give up 20.88% of portfolio value over 90 days. Indaptus Therapeutics is currently does not generate positive expected returns and assumes 4.035% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Indaptus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Indaptus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Indaptus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Indaptus Therapeutics, and traders can use it to determine the average amount a Indaptus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0767
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INDP |
Estimated Market Risk
| 4.04 actual daily | 36 64% of assets are more volatile |
Expected Return
| -0.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Indaptus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Indaptus Therapeutics by adding Indaptus Therapeutics to a well-diversified portfolio.
Indaptus Therapeutics Fundamentals Growth
Indaptus Stock prices reflect investors' perceptions of the future prospects and financial health of Indaptus Therapeutics, and Indaptus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Indaptus Stock performance.
| Return On Equity | -1.88 | ||||
| Return On Asset | -0.86 | ||||
| Current Valuation | 4.83 M | ||||
| Shares Outstanding | 14.43 M | ||||
| Price To Book | 2.67 X | ||||
| EBITDA | (15.37 M) | ||||
| Net Income | (15.02 M) | ||||
| Cash And Equivalents | 33.01 M | ||||
| Cash Per Share | 4.00 X | ||||
| Total Debt | 84.16 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.18 X | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (12.32 M) | ||||
| Earnings Per Share | (1.61) X | ||||
| Market Capitalization | 10.39 M | ||||
| Total Asset | 7.34 M | ||||
| Retained Earnings | (60.44 M) | ||||
| Working Capital | 3.22 M | ||||
About Indaptus Therapeutics Performance
Assessing Indaptus Therapeutics' fundamental ratios provides investors with valuable insights into Indaptus Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Indaptus Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 49.93 | 44.38 | |
| Return On Tangible Assets | (2.05) | (2.15) | |
| Return On Capital Employed | (3.90) | (3.70) | |
| Return On Assets | (2.05) | (2.15) | |
| Return On Equity | (3.81) | (3.62) |
Things to note about Indaptus Therapeutics performance evaluation
Checking the ongoing alerts about Indaptus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Indaptus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Indaptus Therapeutics generated a negative expected return over the last 90 days | |
| Indaptus Therapeutics has some characteristics of a very speculative penny stock | |
| Indaptus Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (15.02 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Indaptus Therapeutics currently holds about 33.01 M in cash with (12.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Indaptus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 42.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20 |
- Analyzing Indaptus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Indaptus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Indaptus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Indaptus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Indaptus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Indaptus Therapeutics' stock. These opinions can provide insight into Indaptus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.